16.02.2024 BB BIOTECH AG  CH0038389992

EQS-Adhoc: BB Biotech AG publishes its 2023 annual report


 

EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Annual Report/Dividend
BB Biotech AG publishes its 2023 annual report

16-Feb-2024 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

February 16, 2024

Annual report of BB Biotech AG as at December 31, 2023 

BB Biotech AG publishes its 2023 annual report

BB Biotech AG published its annual report for fiscal year 2023 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech’s positioning, the investment areas covered by its portfolio and the companies it is invested in.

In 2023, global equity performed better than anticipated by many. The US central bank moderated and then paused interest rate hikes. These developments resulted in a year-end bond market rally and encouraged equity markets further – but led to a noticeable devaluation of the USD, particularly relative to the CHF. Additionally, the year witnessed an uptick in takeover activities. The biotech sector made strong gains as the year closed. BB Biotech achieved significant gains in the fourth quarter. For the full year, BB Biotech’s total share return was ‑18.1% in CHF and -15.2% in EUR, substantially behind the portfolio performance of -7.4% in CHF, -1.3% in EUR and +1.8% in USD. The net loss for BB Biotech in 2023 was CHF 207 mn.

As already announced on January 19, 2024, BB Biotech will propose a dividend of CHF 2.00 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech shares in December 2023. This marks a continuation of the dividend policy of the previous years.

BB Biotech’s annual report 2023 is available under report.bbbiotech.ch/2023/en resp. www.bbbiotech.com

 

For further information:

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Siegfried-Schanz, [email protected]
Maria-Grazia Alderuccio, [email protected]
Claude Mikkelsen, [email protected]


Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, [email protected]

TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28
Thomas Egger, [email protected]

 

www.bbbiotech.com

 

Company profile  
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research. 



End of Inside Information

16-Feb-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: [email protected]
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID: 1838425

 
End of Announcement EQS News Service

1838425  16-Feb-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1838425&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 624,17 5,13 669,48 683,90 0,00 1,28 0,57
EBITDA1,2 588,33 -418,21 624,04 637,31 -390,46 -361,02 -222,29
EBITDA-Marge3 94,26 -8.152,24 93,21 93,19 0,00 -28.204,69
EBIT1,4 588,33 -418,21 624,04 637,31 -390,46 -361,02 -222,29
EBIT-Marge5 94,26 -8.152,24 93,21 93,19 0,00 -28.204,69 -38.998,25
Jahresüberschuss1 587,80 -418,27 622,84 637,24 -390,53 -362,83 -222,41
Netto-Marge6 94,17 -8.153,41 93,03 93,18 0,00 -28.346,09 -39.019,30
Cashflow1,7 225,26 95,66 197,69 241,97 -91,44 234,37 234,97
Ergebnis je Aktie8 10,62 -7,55 11,24 11,51 -7,05 -6,59 -4,05
Dividende8 2,85 2,68 3,20 3,32 3,67 2,88 2,58
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
BB Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0NFN3 45,250 Kaufen 2.506,85
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
32,32 5,42 5,89 114,27
KBV KCV KUV EV/EBITDA
1,05 10,67 4.397,98 -11,28
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
2,88 2,10 4,64 19.03.2025
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
26.04.2024 26.07.2024 25.10.2024 21.02.2025
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
8,22% 3,54% -0,98% -6,70%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu BB BIOTECH AG  ISIN: CH0038389992 können Sie bei EQS abrufen


Biotechnologie , A0NFN3 , BBZA , XETR:BBZA